Excellence in life sciences executive search

Halozyme Retains The Chase Group to Secure Clinical Team

February 9, 2016
The Chase Group has been retained by Halozyme Therapeutics to partner with Dr. Dimitrios Chondros as he builds his clinical team. Halozyme is a clinical stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment.

Chase Group

Share this Content

Copyright © 1993-2024 The Chase Group. All Rights Reserved.